These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 32030887)

  • 21. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
    Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
    Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Problems of diagnostic assessment in advanced pancreatic neuroendocrine neoplasm and treatment implications: a case report and literature review.
    Szymanowski B; Duchnowska R; Bilski M; Łapińska G; Hryciuk B; Kamiński G; Szczylik C
    Nucl Med Rev Cent East Eur; 2016; 19(1):54-7. PubMed ID: 26838946
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and Prognostic Value of PET/CT Imaging with Combination of
    Zhang P; Yu J; Li J; Shen L; Li N; Zhu H; Zhai S; Zhang Y; Yang Z; Lu M
    Contrast Media Mol Imaging; 2018; 2018():2340389. PubMed ID: 29681780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the prognostic values of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in patients with well-differentiated neuroendocrine tumor.
    Sharma P; Naswa N; Kc SS; Alvarado LA; Dwivedi AK; Yadav Y; Kumar R; Ammini AC; Bal C
    Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2194-202. PubMed ID: 25030618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined 18F-FDG PET/CT and 68Ga DOTATATE PET/CT "Superscan" in Metastatic Pancreatic Neuroendocrine Tumor.
    Chan M; Schembri GP
    Clin Nucl Med; 2017 Feb; 42(2):108-109. PubMed ID: 27997429
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ga-68 DOTA-peptides and F-18 FDG PET/CT in patients with neuroendocrine tumor: A review.
    Evangelista L; Ravelli I; Bignotto A; Cecchin D; Zucchetta P
    Clin Imaging; 2020 Nov; 67():113-116. PubMed ID: 32559681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined 68Ga-DOTATOC and 18F-FDG PET Predicts a Double Component With Different Grade of a Pancreatic Neuroendocrine Tumor in a Patient With Multiple Endocrine Neoplasia Type 1.
    Paepegaey AC; Gaujoux S; Meyer C; Rouquette A; Libé R
    Clin Nucl Med; 2020 Jun; 45(6):e281-e282. PubMed ID: 32349092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
    Sampathirao N; Basu S
    J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of 6-18F-fluoro-L-DOPA, 18F-2-deoxy-D-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease.
    Kitano M; Millo C; Rahbari R; Herscovitch P; Gesuwan K; Webb RC; Venkatesan AM; Phan GQ; Hughes MS; Libutti SK; Nilubol N; Linehan WM; Kebebew E
    Surgery; 2011 Dec; 150(6):1122-8. PubMed ID: 22136831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
    Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
    J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach.
    Squires MH; Volkan Adsay N; Schuster DM; Russell MC; Cardona K; Delman KA; Winer JH; Altinel D; Sarmiento JM; El-Rayes B; Hawk N; Staley CA; Maithel SK; Kooby DA
    Ann Surg Oncol; 2015 Jul; 22(7):2295-301. PubMed ID: 25786743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors.
    Abdulrezzak U; Kurt YK; Kula M; Tutus A
    Nucl Med Commun; 2016 Aug; 37(8):874-81. PubMed ID: 27096719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ga-68 DOTATATE PET/CT and F-18 FDG PET/CT in the evaluation of low and intermediate versus high-grade neuroendocrine tumors.
    You H; Kandathil A; Beg M; De Blanche L; Kazmi S; Subramaniam RM
    Nucl Med Commun; 2020 Oct; 41(10):1060-1065. PubMed ID: 32732600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system.
    Ezziddin S; Adler L; Sabet A; Pöppel TD; Grabellus F; Yüce A; Fischer HP; Simon B; Höller T; Biersack HJ; Nagarajah J
    J Nucl Med; 2014 Aug; 55(8):1260-6. PubMed ID: 24876204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biological correlation of ¹⁸F-FDG uptake on PET in pulmonary neuroendocrine tumors.
    Kaira K; Murakami H; Endo M; Ohde Y; Naito T; Kondo H; Nakajima T; Yamamoto N; Takahashi T
    Anticancer Res; 2013 Oct; 33(10):4219-28. PubMed ID: 24122985
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Binderup T; Knigge U; Johnbeck CB; Loft A; Berthelsen AK; Oturai P; Mortensen J; Federspiel B; Langer SW; Kjaer A
    J Nucl Med; 2021 Jun; 62(6):808-815. PubMed ID: 33067340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [
    Chan DL; Hayes AR; Karfis I; Conner A; Mileva M; Bernard E; Schembri G; Navalkissoor S; Gnanasegaran G; Pavlakis N; Marin C; Vanderlinden B; Flamen P; Roach P; Caplin ME; Toumpanakis C; Bailey DL
    J Nucl Med; 2024 Feb; 65(2):185-191. PubMed ID: 38164579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [
    Rinzivillo M; Prosperi D; Mazzuca F; Magi L; Iannicelli E; Pilozzi E; Franchi G; Laghi A; Annibale B; Signore A; Panzuto F
    J Endocrinol Invest; 2021 Apr; 44(4):811-818. PubMed ID: 32767279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 18F-FLT and 18F-FDG positron emission tomography for the imaging of advanced well-differentiated gastro-entero-pancreatic endocrine tumours.
    Giammarile F; Billotey C; Lombard-Bohas C; Le Bars D; Bournaud C; Masson S; Walter T; Houzard C; Scoazec JY; Hervieu V; Vuillez JP; Cornu C; Janier M; Borson-Chazot F
    Nucl Med Commun; 2011 Feb; 32(2):91-7. PubMed ID: 21076344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.
    Ito H; Kondo K; Kawahara T; Kaneta T; Tateishi U; Ueno D; Namura K; Kobayashi K; Miyoshi Y; Yumura Y; Makiyama K; Hayashi N; Hasumi H; Osaka K; Yokomizo Y; Teranishi JI; Hattori Y; Inoue T; Uemura H; Yao M; Nakaigawa N
    Cancer Chemother Pharmacol; 2017 May; 79(5):855-861. PubMed ID: 28331985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.